Anti-oxLDL IgM Antibodies as a Novel Therapy for Metabolic Lipid Diseases
NCT02707211
·
clinicaltrials.gov ↗
EARLY_PHASE1
Phase
UNKNOWN
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Lipid Metabolism, Inborn Errors
Interventions
BIOLOGICAL:
Anti-oxLDL IgM antibody
Sponsor
Universitaire Ziekenhuizen KU Leuven